Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
Is there a role for radiation to the primary mediastinal disease in metastatic thymic neuroendocrine carcinoma with the primary as the only residual disease after systemic therapy?
What dose would you use to treat?
Related Questions
Do you offer adjuvant durvalumab for stage I small cell lung cancer following SBRT or surgery?
Do more fractionated regimens reduce severe toxicity over SBRT in patients with ILD and early-stage NSCLC?
Do you recommend consolidation immunotherapy after SBRT or surgery and chemo for T1-T2N0 SCLC?
Would presence of an SVC stent affect your decision to offer BID vs once-daily chemoradiation for SCLC?
What is the role of consolidative durvalumab and prophylactic cranial irradiation in patients with stage I small cell lung cancer?
In ES-SCLC presenting with extensive brain metastases, how do you time whole brain radiation after the first cycle of chemotherapy has already been delivered?
What is your approach to adjuvant RT or chemoRT in LS-SCLC s/p lobectomy with N1 disease?
Can palliative radiation be used to treat recurrent malignant pleural effusion in NSCLC?
Do you restrict the dose rate during treatment delivery to a pacemaker in addition to limiting the Dmax?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?